<DOC>
	<DOCNO>NCT00621673</DOCNO>
	<brief_summary>Most transient inhibitor formation , , develop within first 4 week . The study monitor whether participant severe Hemophilia A develop inhibitor antibodies later stage switched current recombinant therapy produce Chinese Hamster Ovary ( CHO ) cell line Kogenate-FS raise Baby Hamster Kidney cell line .</brief_summary>
	<brief_title>Assessment Risk Inhibitor Formation Previously Treated Patients With Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Subjects severe hemophilia A ( &lt; 2 % FVIII : C ) Subjects history FVIII inhibitor antibody formation Subjects measurable inhibitor activity Subjects least 200 EDs FVIII concentrate total , include 20 EDs previous 6 month Subjects whose current treatment CHO rFVIII product Subjects elective surgery and/or continuous infusion FVIII administration foreseen study Subjects normal prothrombin time ( PT ) , partial thromboplastin time ( PTT ) compatible FVIII deficiency Subjects bleed disease beside hemophilia A ( , e. , von Willebrand 's disease ) Subjects know intolerance allergic reaction constituent rFVIIIFS know hypersensitivity mouse hamster proteins Any individual past history severe reaction ( ) FVIII concentrate Subjects treatment immunomodulatory agent within last 3 month prior study entry Subjects receive receive experimental drug within 3 month prior study entry Subjects require medication FVIII infusion</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Hemophilia A ,</keyword>
	<keyword>Inhibitor formation ,</keyword>
	<keyword>rFVIII</keyword>
</DOC>